Amivantamab/Lazertinib Improves Survival in EGFR+ Advanced Lung Cancer
Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC.
Related Articles
A Perspective on the MARS2 Trial
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
Decoding cost-effectiveness of PNH therapies
In this issue of Blood, Ito et al1 present a compelling cost-effectiveness analysis of iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH
Assessing purine-analog-based intensive chemotherapy combined with venetoclax for ND and R/R AML
Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, comments on a retrospective analysis assessing the efficacy of combining venetoclax with intensive purine analog-based…
Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML
Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.
Metronomic Capecitabine Improves Upon AIs in HR+/HER2- Metastatic Breast Cancer
The phase 3 MECCA trial represents the largest data set investigating the efficacy of metronomic chemo-endocrine combination therapy in metastatic breast cancer, according to researchers.
FDA Releases Draft Guidance on Tissue Biopsies in Clinical Trials
The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.
Learn about cancer prevention and early detection
When it comes to cancer prevention and early detection, knowledge can be power.
Current Treatment Protocols for Ph+ ALL Treatment
Josep Maria Ribera, MD, PhD, discusses the current standard treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia and the rationale behind them.
Acalabrutinib Regimen Demonstrates Efficacy in De Novo Mantle Cell Lymphoma
An acalabrutinib triplet elicited a high response rate in patients with de novo mantle cell lymphoma.